Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
  • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
  • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts

Definitions

• the present invention relates to physiologically calmative and sedative cough-relieving compositions and a method for relieving cough by the aid of the said compositions.
• Codein morphine monomethyl ether
• other galenic formulations e.g. anisated expectorant liquid, elixir comprising eucalyptus oil or thimal
• Hog-fat is used for the easing of cough in the traditional popular therapy.
• the great disadvantage of the synthetic medicaments is that they comprise smaller or higher amount of exciting alkaloids, therefore certain compositions are considered as doping (stimulating) agents.
• the alkaloids can also have an undesired side-effect to the heart.
• the drawback of the galenic formulations is that their effect is relatively weak. According to French Patent Specification
• compositions according to the present invention comprise hog-fat, eucalyptus oil and optionally mustard in a weight ratio of 700 to 1200 : : 2.5 to 50 : 70 to 160 as active ingredients.
• composition is not sterilized, it should also comprise an antioxidant.
• the weight ratio of hog-fat to the antioxydant should be 700 to 1200 : : 0.1 to 5.
• compositions according to the invention are assured by hog-fat, eucalyptus oil and mustard, latter being optionally present.
• Mustard is not an essential element of the compositions, however, its addition enhances the activity of the compositions.
• the active ingredient of the hog-fat is mainly prostaglandine but also the volatile fatty acids ( triglycerides) have a favourable effect on the inner cilia of the bronchi.
• the active ingredient of cough-relieving and expectorant effect of mustard is mustard oil.
• the cough-relieving effect of eucalyptus oil is known, but in our case it is also useful for the perfuming of the composition.
• the effect of the compositions of the invention is different from the additive effect of hog-fat, eucalyptus oil and mustard which components all have a very low effect per se, as it is widely known. These components synergistically enhance each-others activity.
• compositions exerts their effect partly transdermally, partly by the route of evaporation inhalation.
• the temperature needed for the latter process is assured by the constant temperature of the human body.
• the composition can be sterilized, but the sufficient chemical and microbiological stability can also be assured by addition of an antioxidant.
• an antioxidant preferably butyl hydroxytoluene, commonly used for protecting hog-fat from growing rancid, can be used.
• the active agents of the invention can be applied onto the skin by any means that produces contact of the active agent with the agent's site of action. They can be administered by any conventional means available for use. They can be applied alone, but are generally applied with a pharmaceutical carrier.
• composition When the composition is formulated as a plaster the active ingredients are preferably absorbed by a suitable carrier, optionally covered by a removable protective layer and the carrier is preferably supplied with means suitable for fixing the carrier onto the skin.
• suitable carrier gauze bandage purified cotton, absorbent gauze, terry cloth or any other hydrophobic, soft, non-irritating material can be mentioned.
• the carrier is preferably impregnated on the back side by e.g. a polymer such as polyvinyl chloride, or such a carrier is used of which the back side is of close texture.
• a suitable insulating material e.g. aluminium or polymer foil onto the back side of the carrier.
• the mixture of the active ingredients can be applied onto the chest of the patient confined to bed per se, or absorbed by a suitable carrier, the carrier is preferably fixed onto the skin of the patient.
• the fixing can be carried out by sticking the carrier saturated by the active ingredients on its two or four edges onto the skin by the aid of adhesive plaster stripes, but the carrier can also be put onto a piece of an adhesive plaster being bigger in size than the carrier itself and the parts of the plaster overlaping the carrier fasten the carrier to the akin.
• the adhesive tape can be of the surgical type with an adhesive being neutral from the point of view of skin allergy.
• the tape can be a rubber based one or can have an acrylate coating attached.
• the adhesive tape can be woven or nonwoven fabric.
• That side of the carrier saturated with the active ingredients which will contact the skin is preferably covered by a protective layer which can be removed before use.
• a protective layer polyvinyl chloride, polyethylene or aluminium foil can preferably be used.
• the active ingredients can also be incorporated into creams, dressings, glycerogelatins, pastes and ointments.
• vaseline or any other carrier commonly used in such types of pharmaceutical formulations can be employed as carrier.
• the plaster according to the invention suitable for external application contains from about 1 g to 100 g of active ingredients per unit.
• the active ingredients will ordinarily be present in an amount of about 5 to 100 % by weight based on the total weight of the compositions.
• the composition according to Figure 1 is prepared by saturating the 1 terry cloth piece with the mixture of the active ingredients in an amount of 250 to 2500 g/m 2 , sticking the 2 polyvinyl chloride or other foil to one of ita aides, placing this side onto the 3 adhesive plaster and covering the other side which will be in contact with the skin with the 4 polyvinyl or polyethylene foil which can be removed before use.
• the preferred form of the preparation according to the invention is a square or rectangle with 10 to 20 cm sides.
• the preparation according to the invention has no side-effect, it is not toxic. It exhibits its effect already within 10 to 15 minutes and this effect is exerted throughout 6 to 8 hours. Thereafter the treatment can be repeated without any harmful consequence. Its application is simple, it can be used disregard to the age of the patient and the section of the day.
• the invention is illustrated by the following, non-limiting examples.
• Example 1 hog-fat 1000 g eucalyptus oil 3 g butyl hydroxytoluene 0.1 g
• terry cloth (10x20 cm) is aaturated with the mixture. That side of the terry cloth which will not contact the skin is of close structure in order to prevent the evaporation of the volatile oil and the penetration of hog-fat.
• the carrier saturated like this is applied onto a 13x13 cm piece of an adhesive plaster and that side of the terry cloth which will contact the skin is covered by a polyvinyl chloride foil,
• Example 2 hog-fat 1200 g eucalyptus oil 43 g butyl hydroxytoluene 3 g mustard 90 g
• the above components are mixed and a
• 20x20 cm piece of gauze is aaturated with the mixture, One side of the gauze is impregnated with polyvinyl chloride and it is fixed onto the cheat of the patient by the aid of two atripes of an adhesive plaster being on the opposite sides of the carrier.
• the above components are mixed, thereafter the mixture is sterilized and cooled.
• a hydrophobic textile (10x15 cm) is saturated with this mixture and a polyvinyl chloride foil of the same size is sticked onto that aide of the material which will not contact the akin.
• the carrier is applied onto a 12 x 17 cm piece of an adhesive plaster, thereafter that part of the carrier, which will contact the akin is covered with a polyethylene foil.
• Example 5 Ointment hog-fat 700 g eucalyptus oil 5 g mustard 70 g butyl hydroxytoluene 5 g vaseline 1000 g
• the ingredients are thoroughly mixed.
• the effect of the composition according to the invention is verified by the following tests: The composition according to Example 2 was applied.
• the composition was applied onto the cheat of 17 patients suffering from asthma or bronchitis. The cough completely ceased in the case of 8 patients, it was relieved in great extent in 5 cases and in less extent in 4 cases. The composition was applied for night. No disadvantageous or harmful side-effect could be observed.
• the composition was applied onto the chest of 4 children suffering from double form of chronic bronchitis. The cough was significantly relieved even due to only one treatment and the stethoscopic diagnosis improved as well in all the four cases, c) The composition was applied onto the chest of 10 patients. The results are summarized in Table 1. Table 1
• composition was applied onto the chest of 10 1 to 4 years old and 10, 5 to 14 years old patients suffering from obstructive bronchitis, asthma bronchiale or bronchopneumonia.
• the composition was applied at night, before going to bed for the younger children, while it was used at night and day too, for the elder children, in both cases as a supplement of the basic medicines.
• the younger children (1 to 4 years old) became aubatantially tranquil, they could better sleep, while they auffered from air-thrist before the application of the composition.
• the effect of the composition decreased after about 2 hours.
• a carrier was saturated with mustard and this waa applied to the chest of the same 6 patients. No effect could be observed in any one of the cases.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Botany (AREA)
• Biotechnology (AREA)
• Dermatology (AREA)
• Medical Informatics (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Alternative & Traditional Medicine (AREA)
• Zoology (AREA)
• Hematology (AREA)
• Materials Engineering (AREA)
• Pulmonology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Plant Substances (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=10962279

Family Applications (1)

Country Status (5)

Families Citing this family (4)

Family Cites Families (2)

• 1984
  • 1984-10-12 HU HU823048A patent/HU187414B/hu not_active IP Right Cessation
• 1985
  • 1985-10-11 WO PCT/HU1985/000060 patent/WO1986002270A1/en not_active Application Discontinuation
  • 1985-10-11 EP EP85905100A patent/EP0198003A1/de not_active Withdrawn
  • 1985-10-11 DD DD85281661A patent/DD243642A5/de not_active IP Right Cessation
• 1986
  • 1986-06-12 DK DK277486A patent/DK277486A/da not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events